| Literature DB >> 30728212 |
Xiaofei Shen1, Mingwei Liang1, Xiangyu Chen1, Muhammad Asghar Pasha2, Shanti S D'Souza1, Kelsi Hidde1, Jennifer Howard1, Dil Afroz Sultana1, Ivan Ting Hin Fung1, Longyun Ye1, Jiexue Pan1, Gang Liu1, James R Drake1, Lisa A Drake1, Jinfang Zhu3, Avinash Bhandoola4, Qi Yang5.
Abstract
Group 2 innate lymphoid cells (ILC2) are tissue-resident, long-lived innate effector cells implicated in allergy and asthma. Upon activation, mature ILC2 rapidly secrete large amounts of type-2 cytokines and other effector molecules. The molecular pathways that drive ILC2 activation are not well understood. In this study, we report that the transcriptional controller core binding factor β (CBFβ) is required for ILC2 activation. Deletion or inhibition of CBFβ did not impair the maintenance of ILC2 at homeostasis but abolished ILC2 activation during allergic airway inflammation. Treatment with CBFβ inhibitors prevented ILC2-mediated airway hyperresponsiveness in a mouse model of acute Alternaria allergen inhalation. CBFβ promoted expression of key ILC2 genes at both transcriptional and translational levels. CBF transcriptional complex directly bound to Il13 and Vegfa promoters and enhancers, and controlled gene transcription. CBFβ further promoted ribosome biogenesis and enhanced gene translation in activated ILC2. Together, these data establish an essential role for CBFβ in ILC2 activation.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30728212 PMCID: PMC6401280 DOI: 10.4049/jimmunol.1800852
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422